@phdthesis{MuellerHuebner2020,
  author    = {M{\"u}ller-H{\"u}bner, Laura},
  title     = {The role of nuclear architecture in the context of antigenic variation in Trypanosoma brucei},
  doi       = {10.25972/OPUS-18707},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187074},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Antigenic variation of surface proteins is a commonly used strategy among pathogens to evade the host immune response [63]. The mechanism underlying antigenic variation relies on monoallelic exclusion of a single gene from a hypervariable multigene family combined with repeated, systematic changes in antigen expression. In many systems, these gene families are arranged in subtelomeric contingency loci that are subject to both transcriptional repression and enhanced mutagenesis and recombination [16]. Eviction of a selected gene from a repressed antigen repertoire can be achieved e.g. by recombination into a dedicated, transcriptionally permissive site or by local epigenetic alterations in chromatin composition of the selected gene. Both processes are ultimately affected by genome architecture. Architectural proteins controlling antigenic variation have, however, remained elusive in any pathogen. The unicellular protozoan parasite Trypanosoma brucei evades the host immune response by periodically changing expression of a single variant surface glycoprotein (VSG) from a repertoire of ~3000 VSG genes - the largest mutually exclusively expressed gene family described today. To activate a selected VSG gene, it needs to be located in a dedicated expression site that becomes subject to relocation into a distinct, transcriptionally active subnuclear compartment, the expression site body (ESB). Whereas this emphasizes the importance of nuclear architecture in regulating antigen expression in T. brucei, the mechanisms underlying spatial positioning of DNA in T. brucei are not well understood. In this study I applied genome-wide chromosome conformation capture (Hi-C) to obtain a comprehensive picture of the T. brucei genome in three dimensions, both in procyclic and bloodstream form parasites. Hi-C revealed a highly structured nucleus with megabase chromosomes occupying distinct chromosome territories. Further, specific trans interactions between chromosomes, among which are clusters of centromeres, rRNA genes and procyclins became apparent. With respect to antigenic variation, Hi-C revealed a striking compaction of the subtelomeric VSG gene repertoire and a strong clustering of transcriptionally repressed VSG-containing expression sites. Further, Hi-C analyses confirmed the spatial separation of the actively transcribed from the silenced expression sites in three dimensions. I further sought to characterize architectural proteins mediating nuclear architecture in T. brucei. Whereas CTCF is absent in non-metazoans, we found cohesin to be expressed throughout the cell cycle, emphasizing a function beyond sister chromatid cohesion in S-phase. By Chromatin-Immunoprecipitation with sequencing (ChIPseq), I found cohesin enrichment to coincide with the presence of histone H3 vari- ant (H3.V) and H4 variant (H4.V). Most importantly, cohesin and the histone variants were enriched towards the VSG gene at silent and active expression sites. While the deletion of H3.V led to increased clustering of expression sites in three dimensions and increased chromatin accessibility at expression site promoters, the additional deletion of H4.V increased chromatin accessibility at expression sits even further. RNAseq showed that mutually exclusive VSG expression was lost in H3.V and H4.V single and double deletion mutants. Immunofluorescence imaging of surface VSGs, flow cytometry and single-cell RNAseq revealed a progressive loss of VSG-2 expression, indicative of an increase in VSG switching rate in the H3.V/H4.V double deletion mutants. Using long-read sequencing technology, we found that VSG switching occurred via recombination and concluded, that the concomitant increase in spatial proximity and accessibility among expression sites facilitated the recombination event. I therefore identified the histone variants H3.V and H4.V to act at the interface of global nuclear architecture and chromatin accessibility and to represent a link between genome architecture and antigenic variation.},
  subject      = {Trypanosoma brucei brucei},
  language  = {en}
}
@phdthesis{Hanselmann2023,
  author    = {Hanselmann, Steffen},
  title     = {PRC1 serves as a microtubule-bundling protein and is a potential therapeutic target for lung cancer},
  doi       = {10.25972/OPUS-26631},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266314},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Protein regulator of cytokinesis 1 (PRC1) is a microtubule-associated protein with essential roles in mitosis and cytokinesis. Furthermore, the protein is highly expressed in several cancer types which is correlated with aneuploidy and worse patient outcome. In this study it was investigated, whether PRC1 is a potential target for lung cancer as well as its possible nuclear role. Elevated PRC1 expression was cell cycle-dependent with increasing levels from S-phase to G2/M-phase of the cell cycle. Thereby, PRC1 localized at the nucleus during interphase and at the central spindle and midbody during mitosis and cytokinesis. Genome-wide expression profiling by RNA sequencing of ectopically expressed PRC1 resulted in activation of the p53 pathway. A mutant version of PRC1, that is unable to enter the nucleus, induced the same gene sets as wildtype PRC1, suggesting that PRC1 has no nuclear-specific functions in lung cancer cells. Finally, PRC1 overexpression leads to proliferation defects, multi-nucleation, and enlargement of cells which was directly linked to microtubule-bundling within the cytoplasm. For analysis of the requirement of PRC1 in lung cancer, different inducible cell lines were generated to deplete the protein by RNA interference (RNAi) in vitro. PRC1 depletion caused proliferation defects and cytokinesis failures with increased numbers of bi- and multi-nucleated cells compared to non-induced lung cancer cells. Importantly, effects in control cells were less severe as in lung cancer cells. Finally, p53 wildtype lung cancer cells became senescent, whereas p53 mutant cells became apoptotic upon PRC1 depletion. PRC1 is also required for tumorigenesis in vivo, which was shown by using a mouse model for non-small cell lung cancer driven by oncogenic K-RAS and loss of p53. Here, lung tumor area, tumor number, and high-grade tumors were significantly reduced in PRC1 depleted conditions by RNAi. In this study, it is shown that PRC1 serves as a microtubule-bundling protein with essential roles in mitosis and cytokinesis. Expression of the protein needs to be tightly regulated to allow unperturbed proliferation of lung cancer cells. It is suggested that besides phosphorylation of PRC1, the nuclear localization might be a protective mechanism for the cells to prevent perinuclear microtubule-bundling. In conclusion, PRC1 could be a potential target of lung cancer as mono therapy or in combination with a chemotherapeutic agent, like cisplatin, which enhanced the negative effects on proliferation of lung cancer cells in vitro.},
  language  = {en}
}
@phdthesis{Hagedorn2011,
  author    = {Hagedorn, Ina},
  title     = {Novel mechanisms underlying arterial thrombus formation: in vivo studies in (genetically modified) mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-85752},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Thrombus formation at sites of vascular lesions is a dynamic process that requires a defined series of molecular events including the action of platelet adhesion/activation receptors, intracellular signal transduction, cytoskeletal rearrangements and activation of plasma coagulation factors. This process is essential to limit post-traumatic blood loss but may also contribute to acute thrombotic diseases such as myocardial infarction and stroke. With the help of genetically modified mice and the use of specific protein inhibitors and receptordepleting antibodies, the work presented in this thesis identified novel mechanisms underlying thrombus formation in hemostasis and thrombosis. In the first part of the study, it was shown that von Willebrand Factor (vWF) binding to glycoprotein (GP)Iba is critical for the formation of stable pathological thrombi at high shear rates, suggesting GPIba as an attractive pharmacological target for antithrombotic therapy. The subsequent analysis of recently generated phospholipase (PL)D1-deficient mice identified this enzyme, whose role in platelet function had been largely unknown, as a potential target protein downstream of GPIba. This was based on the finding that PLD1- deficient mice displayed severely defective GPIba-dependent thrombus stabilization under high shear conditions in vitro and in vivo without affecting normal hemostasis. The second part of the thesis characterizes the functional relevance of the immunoreceptor tyrosine-based activation motif (ITAM)-bearing collagen receptor GPVI and the recently identified hemITAM-coupled C-type lectin-like receptor 2 (CLEC-2) for in vivo thrombus formation. Genetic- and antibody-induced GPVI deficiency was found to similarly protect mice from arterial vessel occlusion in three different thrombosis models. These results confirmed GPVI as a promising antithrombotic target and revealed that antibody-treatment had no obvious off-target effects on platelet function. Similarly, immunodepletion of CLEC-2 by treating mice with the specific antibody INU1 resulted in markedly impaired thrombus growth and stabilization under flow in vitro and in vivo. Furthermore, it could be demonstrated that double-immunodepletion of GPVI and CLEC-2 resulted in severely decreased arterial thrombus formation accompanied by dramatically prolonged bleeding times. These data revealed an unexpected redundant function of the two receptors for in vivo thrombus formation and might have important implications for the potential development of anti-GPVI and anti-CLEC-2 antithrombotic agents. The third part of the thesis provides the first functional analysis of megakaryocyte- and platelet-specific RhoA knockout mice. RhoA-deficient mice displayed a defined signaling defect in platelet activation, leading to a profound protection from arterial thrombosis andand ischemic brain infarction, but at the same time also strongly increased bleeding times. These findings identified the GTPase as an important player for thrombus formation in hemostasis and thrombosis. Based on the previous proposal that the coagulation factor (F)XII might represent an ideal target for safe antithrombotic therapy without causing bleeding side effects, the last part of this thesis assesses the antithrombotic potential of the newly generated FXIIa inhibitor rHAInfestin- 4. It was found that rHA-Infestin-4 injection into mice resulted in virtually abolished arterial thrombus formation but no change in bleeding times. Moreover, rHA-Infestin-4 was similarly efficient in a murine model of ischemic stroke, suggesting that the inhibitor might be a promising agent for effective and safe therapy of cardio- and cerebrovascular diseases.},
  subject      = {Thrombus},
  language  = {en}
}